Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

By Smorenburg C.H.   Bontenbal M.   Seynaeve C.   Zuylen C.v.   Heus G.d.   Verweij J.   Wit R.d.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 1, 2001-03 ,pp. : 83-87

Springer Publishing Company

Access to resources Recommend Favorite

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes

By Awada A.   Biganzoli L.   Cufer T.   Beex L.   Lohrisch C.   Batter V.   Hamilton A.   Nooij M.   Piccart M.  

European Journal of Cancer, Vol. 38, Iss. 6, 2002-01 ,pp. : 773-778

Elsevier

Access to resources Recommend Favorite

Phase I Study with a Weekly 1 h Infusion of Paclitaxel in Heavily Pretreated Patients with Metastatic Breast and Ovarian Cancer

By Klaassen U.   Wilke H.   Strumberg D.   Eberhardt W.   Korn M.   Seeber S.  

European Journal of Cancer, Vol. 32, Iss. 3, 1996-03 ,pp. : 547-549

Elsevier

Access to resources Recommend Favorite

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer

By Bartsch Rupert   Wenzel Catharina   Gampenrieder Simon   Pluschnig Ursula   Altorjai Gabriela   Rudas Margaretha   Mader Robert   Dubsky Peter   Rottenfusser Andrea   Gnant Michael   Zielinski Christoph   Steger Guenther  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 5, 2008-10 ,pp. : 903-910

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

By Hayashi Hidetoshi  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 131-136

Springer Publishing Company

Access to resources Recommend Favorite